Most men are already familiar with the PSA test, the prostate-specific antigen test which is the most commonly used blood test to assess prostate cancer risk. But what about genomic testing?
Genomic testing can help determine the metastatic potential of a prostate tumor—the risk that it will spread to other areas of the body—which can in turn help indicate if a minimally invasive treatment (such as Laser Focal Therapy) may be effective. If a biopsy is performed, advanced genomic testing of the biopsy tissue may be recommended using a Decipher Prostate Test to help guide selection of the most appropriate treatment option(s).
At HALO Diagnostics, we use ExoDx from ExosomeDx (a Bio-Techne brand)—a new and unique urine-based test that looks for cancer-specific biomarkers and can help determine a patient’s risk for developing aggressive prostate cancer. This test was validated in two separate clinical studies to determine its reliability. This test is an especially useful tool for men that cannot, for whatever reason, undergo or may experience extreme side effects after biopsy.
This test is important because, while many prostate cancers can be present within the body and grow so slowly that they never threaten a man’s life, other cancers can grow quickly and metastasize to other parts of the body. The ExoDx test analyzes three distinct biomarkers associated with aggressive prostate cancer and provides important insight that can help you know whether to proceed or defer a prostate biopsy.
Biomarker and genomic testing, when used in combination with other forms of testing, offer something very important: Added insight into your specific condition, to assist you in deciding the best course of action. After all, that’s the goal of personalized medicine and a key difference between HALO Diagnostics and other prostate cancer programs.